Avantor, Inc. (NYSE:AVTR) Shares Bought by Norris Perne & French LLP MI

Norris Perne & French LLP MI grew its holdings in Avantor, Inc. (NYSE:AVTR - Free Report) by 91.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 956,625 shares of the company's stock after purchasing an additional 455,963 shares during the quarter. Norris Perne & French LLP MI owned 0.14% of Avantor worth $15,507,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Avantor by 10.5% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,257 shares of the company's stock valued at $132,000 after purchasing an additional 592 shares during the period. American Trust boosted its stake in shares of Avantor by 4.5% in the fourth quarter. American Trust now owns 15,198 shares of the company's stock valued at $320,000 after purchasing an additional 658 shares during the period. Oregon Public Employees Retirement Fund boosted its stake in shares of Avantor by 0.6% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 138,465 shares of the company's stock valued at $2,917,000 after purchasing an additional 765 shares during the period. Smartleaf Asset Management LLC boosted its stake in shares of Avantor by 106.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,611 shares of the company's stock valued at $34,000 after purchasing an additional 830 shares during the period. Finally, Nissay Asset Management Corp Japan ADV lifted its stake in Avantor by 1.0% in the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 82,523 shares of the company's stock worth $1,767,000 after acquiring an additional 857 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company's stock.

Avantor Stock Performance

AVTR traded up $0.29 on Friday, reaching $13.58. The company had a trading volume of 26,592,190 shares, compared to its average volume of 8,263,307. Avantor, Inc. has a 1 year low of $11.82 and a 1 year high of $28.00. The stock has a market capitalization of $9.25 billion, a PE ratio of 13.05, a P/E/G ratio of 1.36 and a beta of 1.04. The company has a quick ratio of 0.75, a current ratio of 1.12 and a debt-to-equity ratio of 0.54. The stock has a 50-day moving average price of $13.40 and a 200-day moving average price of $17.15.

Avantor (NYSE:AVTR - Get Free Report) last announced its quarterly earnings results on Friday, April 25th. The company reported $0.23 earnings per share for the quarter, meeting analysts' consensus estimates of $0.23. Avantor had a net margin of 10.70% and a return on equity of 11.93%. The firm had revenue of $1.58 billion during the quarter, compared to analysts' expectations of $1.61 billion. During the same period in the previous year, the company earned $0.22 earnings per share. Avantor's quarterly revenue was down 5.9% compared to the same quarter last year. As a group, research analysts forecast that Avantor, Inc. will post 1.06 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Cowen downgraded shares of Avantor from a "buy" rating to a "hold" rating in a research note on Monday, April 28th. Wells Fargo & Company dropped their target price on Avantor from $25.00 to $22.00 and set an "overweight" rating on the stock in a report on Thursday, April 17th. Stifel Nicolaus downgraded Avantor from a "buy" rating to a "hold" rating and decreased their price target for the stock from $26.00 to $14.00 in a report on Monday, April 28th. Robert W. Baird lowered their price objective on Avantor from $21.00 to $17.00 and set an "outperform" rating for the company in a research report on Monday, April 28th. Finally, Citigroup dropped their price objective on Avantor from $22.00 to $18.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Seven research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat, Avantor currently has an average rating of "Hold" and an average target price of $18.88.

Insider Activity

In other Avantor news, Director Gregory L. Summe bought 25,000 shares of the business's stock in a transaction dated Wednesday, May 7th. The shares were acquired at an average cost of $12.00 per share, with a total value of $300,000.00. Following the acquisition, the director now directly owns 50,000 shares of the company's stock, valued at $600,000. The trade was a 100.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Joseph R. Massaro bought 8,100 shares of the business's stock in a transaction dated Tuesday, April 29th. The stock was acquired at an average cost of $12.30 per share, for a total transaction of $99,630.00. Following the completion of the acquisition, the director now directly owns 35,038 shares in the company, valued at approximately $430,967.40. This trade represents a 30.07% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 83,100 shares of company stock valued at $1,027,630 in the last ninety days. 1.20% of the stock is currently owned by company insiders.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.